Generic Drugs Market: Global Industry Trends, Manufacturing Process, Share, Size, Growth, Opportunity and Forecast 2018-2023
A generic drug is a pharmaceutical product that is generally intended to be interchangeable with an innovator or a branded drug. Generics are manufactured without a licence from the innovator company and are identical or bio-equivalent to an innovator drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Generic drugs are launched and marketed after the expiry date of the patent or other exclusive rights. Although generic drugs are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price. Unlike branded drug manufacturers who spend millions of dollars on R&D and marketing, generic drug manufacturers do not require such investments. Since the drug’s formula is known, the clinical trials are complete; the generic drug manufacturer’s only requirement is to demonstrate to the regulators that its version is as good and effective as the innovator or branded drug.
According to the IMARC Group, the global generic drugs market was valued at around US$ 244.5 Billion in 2017, growing at a CAGR of around 8% during 2010-2017. The biggest catalyst for growth is an increasing global pharmaceutical spending trend towards generics. Continuously increasing healthcare expenditures have pushed governments and third-party payers to seek ways to control their healthcare expenditures. This is catalyzing an increasing demand for generics versus their branded counterparts. Another major driver of this industry is the continued patent cliff that is providing growing pipelines opportunities for generic firms. Similarly, a growth in the overall global population and aging demographics is also proving to be beneficial for the overall healthcare sector including generic drug manufacturers. Healthcare reforms in the US and other developed markets coupled with strong growth in emerging market are some other important drivers for the generic drugs market.
IMARC’s latest study “Generic Drugs Market: Global Industry Trends, Manufacturing Process, Share, Size, Growth, Opportunity and Forecast 2018-2023” provides a comprehensive roadmap for stakeholders who are planning to setup and run a generic drugs manufacturing plant. The study covers all the requisite aspects of the generic drugs market. This ranges from macro overview of the market, industry performance, processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who are planning to foray into the generic drugs market in any manner.
KEY QUESTIONS ANSWERED IN THIS REPORT:
According to the IMARC Group, the global generic drugs market was valued at around US$ 244.5 Billion in 2017, growing at a CAGR of around 8% during 2010-2017. The biggest catalyst for growth is an increasing global pharmaceutical spending trend towards generics. Continuously increasing healthcare expenditures have pushed governments and third-party payers to seek ways to control their healthcare expenditures. This is catalyzing an increasing demand for generics versus their branded counterparts. Another major driver of this industry is the continued patent cliff that is providing growing pipelines opportunities for generic firms. Similarly, a growth in the overall global population and aging demographics is also proving to be beneficial for the overall healthcare sector including generic drug manufacturers. Healthcare reforms in the US and other developed markets coupled with strong growth in emerging market are some other important drivers for the generic drugs market.
IMARC’s latest study “Generic Drugs Market: Global Industry Trends, Manufacturing Process, Share, Size, Growth, Opportunity and Forecast 2018-2023” provides a comprehensive roadmap for stakeholders who are planning to setup and run a generic drugs manufacturing plant. The study covers all the requisite aspects of the generic drugs market. This ranges from macro overview of the market, industry performance, processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who are planning to foray into the generic drugs market in any manner.
KEY QUESTIONS ANSWERED IN THIS REPORT:
- How has the generic drug market performed so far and how will it perform in the coming years?
- What are the key regional markets in the global generic drug industry?
- What are the various stages in the value chain of the generic drug industry?
- What are the key driving factors and challenges in the generic drug industry?
- What is the structure of the generic drug industry and who are the key players?
- What is the degree of competition in the generic drug industry?
- What are the profit margins in the generic drug industry?
- What are the key requirements for setting up generic drug manufacturing plant?
- How are generic drug manufactured?
- What are the various unit operations involved in generic drug plant?
- What is the total size of land required for setting up generic drug plant?
- What are the machinery requirements for setting up generic drug plant?
- What are the raw material requirements for setting up generic drug plant?
- What are the packaging requirements for generic drug?
- What are the transportation requirements for generic drug?
- What are the utility requirements for setting up generic drug plant?
- What are the manpower requirements for setting up generic drug plant?
- What are the infrastructure costs for setting up generic drug plant?
- What are the capital costs for setting up generic drug plant?
- What are the operating costs for setting up generic drug plant?
- What will be the income and expenditures for generic drug plant?
- What is the time required to break-even?
1 PREFACE
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL GENERIC DRUG INDUSTRY
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Country
5.4 Market Forecast
5.5 SWOT Analysis
5.5.1 Strengths
5.5.2 Weaknesses
5.5.3 Opportunities
5.5.4 Threats
5.6 Value Chain Analysis
5.7 Porter’s Five Forces Analysis
5.7.1 Overview
5.7.2 Bargaining Power of Buyers
5.7.3 Bargaining Power of Suppliers
5.7.4 Degree of Competition
5.7.5 Threat of New Entrants
5.7.6 Threat of Substitutes
5.8 Regulations in Generic Industry
5.9 Key Market Drivers and Success Factors
6 PERFORMANCE OF KEY COUNTRIES
6.1 United States
6.2 China
6.3 Brazil
6.4 Germany
6.5 France
6.6 India
6.7 United Kingdom
6.8 Japan
6.9 Canada
6.10 Italy
6.11 Others
7 COMPETITIVE LANDSCAPE
7.1 Competitive Structure
7.2 Market Breakup by Key Players
7.3 Key Player Profiles
7.3.1 Teva Pharmaceuticals
7.3.2 Novartis
7.3.3 Mylan
7.3.4 Fresenius
7.3.5 Pfizer
8 GENERIC DRUG MANUFACTURING PROCESS
8.1 Product Overview
8.2 Detailed Process Flow (Tablets)
8.3 Detailed Process Flow (Injectable)
8.4 Various Types of Unit Operations Involved
8.5 Mass Balance and Raw Material Requirements
9 PROJECT DETAILS, REQUIREMENTS AND COSTS INVOLVED
9.1 Land Requirements and Expenditures
9.2 Construction Requirements and Expenditures
9.3 Plant Machinery
9.4 Machinery Pictures
9.5 Raw Material Requirements and Expenditures
9.6 Packaging Requirements and Expenditures
9.7 Transportation Requirements and Expenditures
9.8 Utility Requirements and Expenditures
9.9 Manpower Requirements and Expenditures
9.10 Other Capital Investments
10 LOANS AND FINANCIAL ASSISTANCE
11 PROJECT ECONOMICS
11.1 Capital Cost of the Project
11.2 Techno-Economic Parameters
11.3 Product Pricing and Margins Across Various Levels of the Supply Chain
11.4 Taxation and Depreciation
11.5 Income Projections
11.6 Expenditure Projections
11.7 Financial Analysis
11.8 Profit Analysis
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL GENERIC DRUG INDUSTRY
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Country
5.4 Market Forecast
5.5 SWOT Analysis
5.5.1 Strengths
5.5.2 Weaknesses
5.5.3 Opportunities
5.5.4 Threats
5.6 Value Chain Analysis
5.7 Porter’s Five Forces Analysis
5.7.1 Overview
5.7.2 Bargaining Power of Buyers
5.7.3 Bargaining Power of Suppliers
5.7.4 Degree of Competition
5.7.5 Threat of New Entrants
5.7.6 Threat of Substitutes
5.8 Regulations in Generic Industry
5.9 Key Market Drivers and Success Factors
6 PERFORMANCE OF KEY COUNTRIES
6.1 United States
6.2 China
6.3 Brazil
6.4 Germany
6.5 France
6.6 India
6.7 United Kingdom
6.8 Japan
6.9 Canada
6.10 Italy
6.11 Others
7 COMPETITIVE LANDSCAPE
7.1 Competitive Structure
7.2 Market Breakup by Key Players
7.3 Key Player Profiles
7.3.1 Teva Pharmaceuticals
7.3.2 Novartis
7.3.3 Mylan
7.3.4 Fresenius
7.3.5 Pfizer
8 GENERIC DRUG MANUFACTURING PROCESS
8.1 Product Overview
8.2 Detailed Process Flow (Tablets)
8.3 Detailed Process Flow (Injectable)
8.4 Various Types of Unit Operations Involved
8.5 Mass Balance and Raw Material Requirements
9 PROJECT DETAILS, REQUIREMENTS AND COSTS INVOLVED
9.1 Land Requirements and Expenditures
9.2 Construction Requirements and Expenditures
9.3 Plant Machinery
9.4 Machinery Pictures
9.5 Raw Material Requirements and Expenditures
9.6 Packaging Requirements and Expenditures
9.7 Transportation Requirements and Expenditures
9.8 Utility Requirements and Expenditures
9.9 Manpower Requirements and Expenditures
9.10 Other Capital Investments
10 LOANS AND FINANCIAL ASSISTANCE
11 PROJECT ECONOMICS
11.1 Capital Cost of the Project
11.2 Techno-Economic Parameters
11.3 Product Pricing and Margins Across Various Levels of the Supply Chain
11.4 Taxation and Depreciation
11.5 Income Projections
11.6 Expenditure Projections
11.7 Financial Analysis
11.8 Profit Analysis
LIST OF TABLES
Table 1: Global: Generic Drug Market: Key Industry Highlights, 2017 and 2023
Table 2: Global: Generic Drug Market Forecast: Breakup by Country (in Million US$), 2018 - 2023
Table 3: Generic Drug Manufacturing Plant: Costs Related to Land and Site Development (in US$)
Table 4: Generic Drug Manufacturing Plant: Costs Related to Civil Works (in US$)
Table 5: Generic Drug Manufacturing Plant: Costs Related to Machinery Unit (in US$)
Table 6: Generic Drug Manufacturing Plant: Raw Material Requirements
Table 7: Generic Drug Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
Table 8: Generic Drug Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
Table 9: Details of Financial Assistance Offered by Financial Institutions
Table 10: Generic Drug Manufacturing Plant: Capital Costs (in US$)
Table 11: Generic Drug Manufacturing Plant: Techno-Economic Parameters
Table 12: Generic Drug Manufacturing Plant: Taxation and Depreciation (in US$)
Table 13: Generic Drug Manufacturing Plant: Income Projections (in US$)
Table 14: Generic Drug Manufacturing Plant: Expenditure Projections (in US$)
Table 15: Generic Drug Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability
Table 16: Generic Drug Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability
Table 17: Generic Drug Manufacturing Plant: Profit and Loss Account
Table 1: Global: Generic Drug Market: Key Industry Highlights, 2017 and 2023
Table 2: Global: Generic Drug Market Forecast: Breakup by Country (in Million US$), 2018 - 2023
Table 3: Generic Drug Manufacturing Plant: Costs Related to Land and Site Development (in US$)
Table 4: Generic Drug Manufacturing Plant: Costs Related to Civil Works (in US$)
Table 5: Generic Drug Manufacturing Plant: Costs Related to Machinery Unit (in US$)
Table 6: Generic Drug Manufacturing Plant: Raw Material Requirements
Table 7: Generic Drug Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
Table 8: Generic Drug Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
Table 9: Details of Financial Assistance Offered by Financial Institutions
Table 10: Generic Drug Manufacturing Plant: Capital Costs (in US$)
Table 11: Generic Drug Manufacturing Plant: Techno-Economic Parameters
Table 12: Generic Drug Manufacturing Plant: Taxation and Depreciation (in US$)
Table 13: Generic Drug Manufacturing Plant: Income Projections (in US$)
Table 14: Generic Drug Manufacturing Plant: Expenditure Projections (in US$)
Table 15: Generic Drug Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability
Table 16: Generic Drug Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability
Table 17: Generic Drug Manufacturing Plant: Profit and Loss Account
LIST OF FIGURES
Figure 1: Global: Generic Drug Industry Overview
Figure 2: Global: Generic Drug Market: Sales Value Trends (in Billion US$), 2010 - 2017
Figure 3: Global: Generic Drug Market Forecast: Sales Value Trends (in Billion US$), 2018 - 2023
Figure 4: Global: Generic Drug Market: Breakup by Country (in %), 2017
Figure 5: Global: Generic Drug Industry: SWOT Analysis
Figure 6: Global: Generic Drug Industry: Value Chain Analysis
Figure 7: Global: Generic Drug Industry: Porter’s Five Forces Analysis
Figure 8: USA: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 9: China: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 10: Brazil: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 11: Germany: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 12: France: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 13: Generic Drug Industry: Profit Margins at Various Levels of the Supply Chain
Figure 14: Generic Drug Manufacturing: Production Cost Breakup (in %)
Figure 15: Generic Drug Manufacturing Plant: Detailed Process Flow
Figure 16: Generic Drug Manufacturing Process: Conversion Rate of Feedstocks
Figure 17: Generic Drug Manufacturing Plant: Proposed Plant Layout
Figure 18: Generic Drug Manufacturing Plant: Breakup of Capital Costs (in %)
Figure 1: Global: Generic Drug Industry Overview
Figure 2: Global: Generic Drug Market: Sales Value Trends (in Billion US$), 2010 - 2017
Figure 3: Global: Generic Drug Market Forecast: Sales Value Trends (in Billion US$), 2018 - 2023
Figure 4: Global: Generic Drug Market: Breakup by Country (in %), 2017
Figure 5: Global: Generic Drug Industry: SWOT Analysis
Figure 6: Global: Generic Drug Industry: Value Chain Analysis
Figure 7: Global: Generic Drug Industry: Porter’s Five Forces Analysis
Figure 8: USA: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 9: China: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 10: Brazil: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 11: Germany: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 12: France: Generic Drug Market (in Million US$), 2010, 2017 & 2023
Figure 13: Generic Drug Industry: Profit Margins at Various Levels of the Supply Chain
Figure 14: Generic Drug Manufacturing: Production Cost Breakup (in %)
Figure 15: Generic Drug Manufacturing Plant: Detailed Process Flow
Figure 16: Generic Drug Manufacturing Process: Conversion Rate of Feedstocks
Figure 17: Generic Drug Manufacturing Plant: Proposed Plant Layout
Figure 18: Generic Drug Manufacturing Plant: Breakup of Capital Costs (in %)
